Shares of NewLink Genetics Corp (NASDAQ:NLNK) have earned an average recommendation of “Buy” from the nine analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $25.67.
A number of equities research analysts have issued reports on the company. Cantor Fitzgerald set a $26.00 price target on NewLink Genetics and gave the stock a “buy” rating in a research note on Monday, January 8th. BidaskClub upgraded NewLink Genetics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Zacks Investment Research lowered NewLink Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, January 4th. Jefferies Group cut their price target on NewLink Genetics from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, November 3rd. Finally, Stifel Nicolaus increased their price target on NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd.
Shares of NewLink Genetics (NASDAQ NLNK) traded up $0.14 during trading on Tuesday, reaching $8.58. The company had a trading volume of 739,600 shares, compared to its average volume of 1,120,267. NewLink Genetics has a one year low of $5.90 and a one year high of $25.17. The company has a market cap of $313.68, a PE ratio of -3.52 and a beta of 1.10.
NewLink Genetics (NASDAQ:NLNK) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.05. NewLink Genetics had a negative return on equity of 63.39% and a negative net margin of 229.19%. research analysts anticipate that NewLink Genetics will post -2.65 EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of NewLink Genetics by 1,823.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,269 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 9,735 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of NewLink Genetics during the third quarter valued at about $114,000. Advisor Group Inc. grew its position in shares of NewLink Genetics by 3.4% during the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 600 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of NewLink Genetics by 3.0% during the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 556 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in shares of NewLink Genetics by 21.5% during the second quarter. Parametric Portfolio Associates LLC now owns 27,972 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 4,955 shares in the last quarter. Hedge funds and other institutional investors own 52.63% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “NewLink Genetics Corp (NLNK) Given Average Rating of “Buy” by Analysts” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/16/newlink-genetics-corp-nlnk-given-average-rating-of-buy-by-analysts.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.